Clinical Trial Update: Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO) [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial comparing ranibizumab alone versus a combination with triamcinolone acetate for ophthalmopathy in phase 2 and phase 3 stages; status is unknown…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ophthalmopathy

Drugs mentioned

• Ranibizumab (ranibizumab)
• Triamcinolone Acetate (triamcinolone acetate)

Snippet

Sponsor: Assiut University | Conditions: Ophthalmopathy | Phase 2, Phase 3 | Status: UNKNOWN